首页 > 最新文献

Cancer Nanotechnology最新文献

英文 中文
pH-sensitive polymeric micelles enhance the co-delivery of doxorubicin and docetaxel: an emerging modality for treating breast cancer 对 pH 值敏感的聚合物胶束可增强多柔比星和多西他赛的联合给药:一种治疗乳腺癌的新兴模式
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-07-20 DOI: 10.1186/s12645-024-00275-1
Leila Farhoudi, Seyedeh Maryam Hosseinikhah, Amin Kazemi-Beydokhti, Leila Arabi, Seyedeh Hoda Alavizadeh, Seyedeh Alia Moosavian, Mahmoud Reza Jaafari
Designing and preparing a co-delivery system based on polymeric micelles have attracted in recent years. Co-delivery of anti-cancer agents within pH-sensitive polymeric micelles could provide superior advantages over the co-administration of free drugs, since it enables simultaneous delivery of drugs to reach an optimum synergistic dose right to the tumor. DOX was conjugated to the polymer through a hydrazine linker by Schiff’s base reaction. Then, DTX was encapsulated into the core of the polymer to the resulting DOX-Hyd-PM/DTX micelle with optimum molar ratios of 1:1 and 1:5 (DOX/DTX). The final formulations showed the desired particle size and increased release of DOX and DTX in acidic media (pH 5.5). The cytotoxicity assay of DOX-Hyd-PM/DTX indicated the highest synergistic effect on both 4T1 and TUBO cell lines over other formulations. Interestingly, in accordance with in vitro results, DOX-Hyd-PM/DTX revealed a promising anti-tumor activity in mice-bearing 4T1 breast cancer tumor with higher tumor accumulation of DOX and DTX after 24 h compared to free drugs combination. These findings point to the potential use of such smart nanodrug delivery systems in cancer treatment, where the synergistic effect of both drugs may be used to enhance therapeutic response.
近年来,设计和制备基于聚合物胶束的联合给药系统备受关注。在对 pH 值敏感的聚合物胶束中联合投放抗癌药物比联合投放游离药物更有优势,因为它能同时投放药物,以达到直达肿瘤的最佳协同剂量。通过席夫碱反应,DOX 通过肼连接物与聚合物共轭。然后,DTX 被包裹到聚合物的核心中,形成 DOX-Hyd-PM/DTX 胶束,最佳摩尔比为 1:1 和 1:5(DOX/DTX)。最终制剂显示出理想的粒度,并增加了 DOX 和 DTX 在酸性介质(pH 5.5)中的释放量。DOX-Hyd-PM/DTX的细胞毒性试验表明,与其他制剂相比,DOX-Hyd-PM/DTX对4T1和TUBO细胞株的协同效应最高。有趣的是,与体外结果一致,DOX-Hyd-PM/DTX 在小鼠 4T1 乳腺癌肿瘤中显示出良好的抗肿瘤活性,与游离药物组合相比,24 小时后 DOX 和 DTX 在肿瘤中的蓄积量更高。这些研究结果表明,这种智能纳米给药系统可用于癌症治疗,两种药物的协同作用可提高治疗效果。
{"title":"pH-sensitive polymeric micelles enhance the co-delivery of doxorubicin and docetaxel: an emerging modality for treating breast cancer","authors":"Leila Farhoudi, Seyedeh Maryam Hosseinikhah, Amin Kazemi-Beydokhti, Leila Arabi, Seyedeh Hoda Alavizadeh, Seyedeh Alia Moosavian, Mahmoud Reza Jaafari","doi":"10.1186/s12645-024-00275-1","DOIUrl":"https://doi.org/10.1186/s12645-024-00275-1","url":null,"abstract":"Designing and preparing a co-delivery system based on polymeric micelles have attracted in recent years. Co-delivery of anti-cancer agents within pH-sensitive polymeric micelles could provide superior advantages over the co-administration of free drugs, since it enables simultaneous delivery of drugs to reach an optimum synergistic dose right to the tumor. DOX was conjugated to the polymer through a hydrazine linker by Schiff’s base reaction. Then, DTX was encapsulated into the core of the polymer to the resulting DOX-Hyd-PM/DTX micelle with optimum molar ratios of 1:1 and 1:5 (DOX/DTX). The final formulations showed the desired particle size and increased release of DOX and DTX in acidic media (pH 5.5). The cytotoxicity assay of DOX-Hyd-PM/DTX indicated the highest synergistic effect on both 4T1 and TUBO cell lines over other formulations. Interestingly, in accordance with in vitro results, DOX-Hyd-PM/DTX revealed a promising anti-tumor activity in mice-bearing 4T1 breast cancer tumor with higher tumor accumulation of DOX and DTX after 24 h compared to free drugs combination. These findings point to the potential use of such smart nanodrug delivery systems in cancer treatment, where the synergistic effect of both drugs may be used to enhance therapeutic response. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"12 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141742304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracellular vesicle miRNAs for predicting the efficacy of late-line treatment with anlotinib in patients with lung adenocarcinoma 预测肺腺癌患者接受安罗替尼晚线治疗疗效的细胞外囊泡miRNA
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-07-02 DOI: 10.1186/s12645-024-00273-3
Aimi Huang, Fuchuang Zhang, Jiyang Zhang, Xiaoya Xu, Zhikuan Li, Sheng Chen, Baoning Nian, Dadong Zhang, Baohui Han, Aiqin Gu, Weimin Wang
Anlotinib is a targeted therapy indicated for some malignancies, including advanced non-small cell lung cancer (NSCLC). However, noninvasive biomarkers for identifying patients who will benefit from this disease remain lacking. Here, we investigated the potential of small extracellular vesicle (sEV) microRNAs (miRNAs) as predictive biomarkers for anlotinib efficacy. A total of 20 advanced NSCLC patients were enrolled. Patients were classified as having stable disease (SD) or progressive disease (PD) after the initial efficacy assessment. Seven differentially expressed miRNAs (DEMs) were identified. Among them, miR-941 was significantly upregulated in the PD group, while the others were downregulated. Furthermore, these six downregulated miRNAs (miR-30a-3p, miR-150-5p, miR-122-5p, miR-10b-5p, miR-92a-3p, and miR-150-3p) were more pronounced in nonsmoking patients. It was found that sEV miRNAs have the potential to predict the benefit of anlotinib.
安罗替尼是一种适用于包括晚期非小细胞肺癌(NSCLC)在内的某些恶性肿瘤的靶向疗法。然而,目前仍缺乏非侵入性生物标志物来识别将从这种疾病中获益的患者。在这里,我们研究了细胞外小泡(sEV)微RNA(miRNA)作为安罗替尼疗效预测生物标志物的潜力。共招募了20名晚期NSCLC患者。初步疗效评估后,患者被分为病情稳定(SD)和病情进展(PD)两类。研究发现了七种差异表达的 miRNA(DEMs)。其中,miR-941 在进展期组显著上调,而其他则下调。此外,这六个下调的 miRNA(miR-30a-3p、miR-150-5p、miR-122-5p、miR-10b-5p、miR-92a-3p 和 miR-150-3p)在非吸烟患者中更为明显。研究发现,sEV miRNAs有可能预测安罗替尼的疗效。
{"title":"Extracellular vesicle miRNAs for predicting the efficacy of late-line treatment with anlotinib in patients with lung adenocarcinoma","authors":"Aimi Huang, Fuchuang Zhang, Jiyang Zhang, Xiaoya Xu, Zhikuan Li, Sheng Chen, Baoning Nian, Dadong Zhang, Baohui Han, Aiqin Gu, Weimin Wang","doi":"10.1186/s12645-024-00273-3","DOIUrl":"https://doi.org/10.1186/s12645-024-00273-3","url":null,"abstract":"Anlotinib is a targeted therapy indicated for some malignancies, including advanced non-small cell lung cancer (NSCLC). However, noninvasive biomarkers for identifying patients who will benefit from this disease remain lacking. Here, we investigated the potential of small extracellular vesicle (sEV) microRNAs (miRNAs) as predictive biomarkers for anlotinib efficacy. A total of 20 advanced NSCLC patients were enrolled. Patients were classified as having stable disease (SD) or progressive disease (PD) after the initial efficacy assessment. Seven differentially expressed miRNAs (DEMs) were identified. Among them, miR-941 was significantly upregulated in the PD group, while the others were downregulated. Furthermore, these six downregulated miRNAs (miR-30a-3p, miR-150-5p, miR-122-5p, miR-10b-5p, miR-92a-3p, and miR-150-3p) were more pronounced in nonsmoking patients. It was found that sEV miRNAs have the potential to predict the benefit of anlotinib.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"49 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141510326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biocompatible PLGA-PCL nanobeads for efficient delivery of curcumin to lung cancer 生物相容性 PLGA-PCL 纳米吸附剂用于向肺癌患者高效递送姜黄素
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-06-24 DOI: 10.1186/s12645-024-00272-4
Sheida Sadeghi, Javad Mohammadnejad, Akram Eidi, Hanieh Jafary
Lung cancer has been mentioned as the first and second most prevalent cancer among males and females worldwide, respectively since conventional approaches do not have enough efficiency in its suppression. Therefore, a biocompatible and efficient polylactic-co-glycolic acid (PLGA: P)- poly-ε-caprolactone (PCL: P) copolymer was fabricated for delivery of relatively insoluble curcumin (Cur) to A549 lung cancer cells. Next, the physicochemical aspects of the synthesized nanobeads were characterized by applying analytical sets, including FT-IR, DLS, TEM, and TGA as nano-metric size (20–45 nm) and 1.29% of Cur entrapment efficiency were determined for P-P-Cur nano-beads. Thereafter, a controlled (5% within 2 h at pH 7.4) and pH-sensitive (nearly 50% within 4 h at pH 5.0) drug release manner was observed for P-P-Cur nanobeads. Thereafter, biomedical assays were conducted for the cancer suppression ability of nanobeads. 41% cell viability after 24 h of treatment with 200 nM concentration and 7.55% cell cycle arrest at 5 h of post-treatment with 100 nM (IC50) concentration were attained for P-P-Cur. Also, 7-fold increase and 2-fold decrease in the expressions of Caspase-9 (apoptotic gene) and Bcl2 (anti-apoptotic gene) were observed which have further approved the cancer inhibition potency of the P-P-Cur sample. The cellular uptake results indicated 91% internalization in A549 cells while it was less than 1% for the pure Cur. These data have demonstrated that P-P-Cur can use as a biocompatible drug delivery system for Cur and treatment of lung cancer.
肺癌在全球男性和女性癌症发病率中分别位居第一和第二位,而传统方法对肺癌的抑制效果不佳。因此,研究人员制备了一种生物相容性好且高效的聚乳酸-聚甘醇酸(PLGA:P)-聚ε-己内酯(PCL:P)共聚物,用于向 A549 肺癌细胞递送相对不溶性的姜黄素(Cur)。接着,应用 FT-IR、DLS、TEM 和 TGA 等分析装置对合成的纳米珠的理化性质进行了表征,确定了 P-P-Cur 纳米珠的纳米尺寸(20-45 nm)和 1.29% 的姜黄素包载效率。此后,观察到 P-P-Cur 纳米珠的药物释放方式具有可控性(pH 值为 7.4 时,2 小时内释放 5%)和 pH 值敏感性(pH 值为 5.0 时,4 小时内释放近 50%)。随后,对纳米珠的抑癌能力进行了生物医学实验。在使用 200 nM 浓度的 P-P-Cur 处理 24 小时后,细胞存活率达到 41%;在使用 100 nM(IC50)浓度的 P-P-Cur 处理 5 小时后,细胞周期停滞率达到 7.55%。此外,还观察到 Caspase-9(凋亡基因)和 Bcl2(抗凋亡基因)的表达量分别增加了 7 倍和减少了 2 倍,这进一步证实了 P-P-Cur 样品的抑癌功效。细胞吸收结果表明,A549 细胞的内化率为 91%,而纯 Cur 的内化率不到 1%。这些数据表明,P-P-Cur 可作为一种生物相容性药物递送系统,用于 Cur 和肺癌的治疗。
{"title":"Biocompatible PLGA-PCL nanobeads for efficient delivery of curcumin to lung cancer","authors":"Sheida Sadeghi, Javad Mohammadnejad, Akram Eidi, Hanieh Jafary","doi":"10.1186/s12645-024-00272-4","DOIUrl":"https://doi.org/10.1186/s12645-024-00272-4","url":null,"abstract":"Lung cancer has been mentioned as the first and second most prevalent cancer among males and females worldwide, respectively since conventional approaches do not have enough efficiency in its suppression. Therefore, a biocompatible and efficient polylactic-co-glycolic acid (PLGA: P)- poly-ε-caprolactone (PCL: P) copolymer was fabricated for delivery of relatively insoluble curcumin (Cur) to A549 lung cancer cells. Next, the physicochemical aspects of the synthesized nanobeads were characterized by applying analytical sets, including FT-IR, DLS, TEM, and TGA as nano-metric size (20–45 nm) and 1.29% of Cur entrapment efficiency were determined for P-P-Cur nano-beads. Thereafter, a controlled (5% within 2 h at pH 7.4) and pH-sensitive (nearly 50% within 4 h at pH 5.0) drug release manner was observed for P-P-Cur nanobeads. Thereafter, biomedical assays were conducted for the cancer suppression ability of nanobeads. 41% cell viability after 24 h of treatment with 200 nM concentration and 7.55% cell cycle arrest at 5 h of post-treatment with 100 nM (IC50) concentration were attained for P-P-Cur. Also, 7-fold increase and 2-fold decrease in the expressions of Caspase-9 (apoptotic gene) and Bcl2 (anti-apoptotic gene) were observed which have further approved the cancer inhibition potency of the P-P-Cur sample. The cellular uptake results indicated 91% internalization in A549 cells while it was less than 1% for the pure Cur. These data have demonstrated that P-P-Cur can use as a biocompatible drug delivery system for Cur and treatment of lung cancer.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"35 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141530125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Black TiO2-based nanoparticles as Toll-like receptor stimulator delivery system for enhanced photothermal-immunotherapy of pancreatic cancer 以黑色 TiO2 为基础的纳米粒子作为 Toll 样受体刺激剂递送系统,用于增强胰腺癌的光热免疫疗法
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-06-04 DOI: 10.1186/s12645-024-00266-2
Liu Xu, Ruoyu Wu, Jiajing Ni, Lufei Jin, Kaiwei Xu, Yuchao Zhu, Lu Hong, Chunqu Chen, Linwei Wang, Lubin Zhu, Weijian Zhou, Wenqi Shen, Jianhua Wang
The tumor-specific immune responses, essential for removing residual lesions and preventing tumor metastases, can be stimulated by tumor-associated antigens (TAAs) released following photothermal therapy (PTT). However, due to the immunosuppressed microenvironment of pancreatic ductal adenocarcinoma (PDAC), the TAAs released by PTT are difficult to induce an effective immune response. In this work, we prepared the mesoporous silica (mSiO2) coated black titanium dioxide (bTiO2) photothermal nanoparticles (NPs) for enhanced photothermal-immunotherapy toward PDAC, in which resiquimod (R848) was loaded and DOTA-Gd was conjugated. The NPs are specified as bTiO2@mSiO2@Gd/R848 and abbreviated to NPs/R848. R848 as a kind of Toll-like receptor 7/8 agonist can remodel the tumor microenvironment (TME) in PDAC and induce a strong immune response. Furthermore, DOTA-Gd serves as a magnetic resonance imaging (MRI) contrast agent to improve the T1-weighted MRI performance of the NPs. In vitro results of this study show that NPs/R848 could thermally ablate tumor cells and efficiently trigger dendritic cell (DC) maturation. The results of in vivo investigations demonstrate that the combined use of photothermal-immunotherapy exhibits a significant inhibitory effect on tumor growth. Besides, it promoted maturation of DCs and enhanced infiltration of CD8 + , CD4 + T cells to improve the TME in PDAC. Our study anticipates that by encouraging the maturation of DCs, this strategy will improve the TME and enable the successful photothermal-immunotherapy of PDAC.
光热疗法(PTT)释放的肿瘤相关抗原(TAAs)可刺激肿瘤特异性免疫反应,这对清除残余病灶和防止肿瘤转移至关重要。然而,由于胰腺导管腺癌(PDAC)的免疫抑制微环境,PTT释放的TAA很难诱导有效的免疫反应。在这项研究中,我们制备了介孔二氧化硅(mSiO2)包覆黑色二氧化钛(bTiO2)的光热纳米颗粒(NPs),用于增强对PDAC的光热免疫疗法。NPs的名称为bTiO2@mSiO2@Gd/R848,缩写为NPs/R848。R848是一种Toll样受体7/8激动剂,能重塑PDAC的肿瘤微环境(TME)并诱导强烈的免疫反应。此外,DOTA-Gd 可作为磁共振成像(MRI)造影剂,改善 NPs 的 T1 加权 MRI 性能。本研究的体外研究结果表明,NPs/R848可以热消融肿瘤细胞,并有效地触发树突状细胞(DC)成熟。体内研究结果表明,联合使用光热免疫疗法对肿瘤生长有显著的抑制作用。此外,它还促进了 DC 的成熟,并增强了 CD8 +、CD4 + T 细胞的浸润,从而改善了 PDAC 的 TME。我们的研究预计,通过促进DCs的成熟,这一策略将改善TME,使PDAC的光热免疫疗法获得成功。
{"title":"Black TiO2-based nanoparticles as Toll-like receptor stimulator delivery system for enhanced photothermal-immunotherapy of pancreatic cancer","authors":"Liu Xu, Ruoyu Wu, Jiajing Ni, Lufei Jin, Kaiwei Xu, Yuchao Zhu, Lu Hong, Chunqu Chen, Linwei Wang, Lubin Zhu, Weijian Zhou, Wenqi Shen, Jianhua Wang","doi":"10.1186/s12645-024-00266-2","DOIUrl":"https://doi.org/10.1186/s12645-024-00266-2","url":null,"abstract":"The tumor-specific immune responses, essential for removing residual lesions and preventing tumor metastases, can be stimulated by tumor-associated antigens (TAAs) released following photothermal therapy (PTT). However, due to the immunosuppressed microenvironment of pancreatic ductal adenocarcinoma (PDAC), the TAAs released by PTT are difficult to induce an effective immune response. In this work, we prepared the mesoporous silica (mSiO2) coated black titanium dioxide (bTiO2) photothermal nanoparticles (NPs) for enhanced photothermal-immunotherapy toward PDAC, in which resiquimod (R848) was loaded and DOTA-Gd was conjugated. The NPs are specified as bTiO2@mSiO2@Gd/R848 and abbreviated to NPs/R848. R848 as a kind of Toll-like receptor 7/8 agonist can remodel the tumor microenvironment (TME) in PDAC and induce a strong immune response. Furthermore, DOTA-Gd serves as a magnetic resonance imaging (MRI) contrast agent to improve the T1-weighted MRI performance of the NPs. In vitro results of this study show that NPs/R848 could thermally ablate tumor cells and efficiently trigger dendritic cell (DC) maturation. The results of in vivo investigations demonstrate that the combined use of photothermal-immunotherapy exhibits a significant inhibitory effect on tumor growth. Besides, it promoted maturation of DCs and enhanced infiltration of CD8 + , CD4 + T cells to improve the TME in PDAC. Our study anticipates that by encouraging the maturation of DCs, this strategy will improve the TME and enable the successful photothermal-immunotherapy of PDAC.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"43 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141254113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a novel nanoformulation based on aloe vera-derived carbon quantum dot and chromium-doped alumina nanoparticle (Al2O3:Cr@Cdot NPs): evaluating the anticancer and antimicrobial activities of nanoparticles in photodynamic therapy 基于芦荟提取的碳量子点和掺铬氧化铝纳米粒子(Al2O3:Cr@Cdot NPs)的新型纳米制剂的开发:评估纳米粒子在光动力疗法中的抗癌和抗菌活性
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-06-03 DOI: 10.1186/s12645-024-00260-8
Merat Karimi, Mina Homayoonfal, Mostafa Zahedifar, Amirreza Ostadian, Reyhaneh Adibi, Bahareh Mohammadzadeh, Arash Raisi, Fatemeh Ravaei, Somaye Rashki, Mahsa Khakbraghi, Michael Hamblin, Zahra Kheirkhah, Ehsan Sadeghi, Majid Nejati, Hamed Mirzaei
The objective of this study was to synthesize a novel antibacterial and anticancer nanoformulation using aloe vera-derived carbon quantum dots (Cdot) and chromium-doped alumina nanoparticles (Al2O3:Cr/Cdot NPs) via a sol–gel method. X-ray diffraction (XRD) analysis confirmed crystalline NPs with a size range of 10–12 nm, while energy-dispersive X-ray spectroscopy (EDS) revealed their elemental composition without impurities. Fourier-transform infrared spectroscopy (FT-IR) indicated strong interactions between Cdot and Al2O3:Cr NPs, forming a robust heterostructure. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) images provided visual confirmation of monodisperse, spherical NPs, ensuring uniformity for further applications. Evaluation of reactive oxygen species (ROS) demonstrated superior generation of singlet oxygen and hydroxyl radicals by Al2O3:Cr/Cdot NPs, essential for photodynamic therapy. Minimum inhibitory concentration (MIC) tests revealed potent antibacterial activity against drug-resistant bacteria, inhibiting biofilm formation by 89% and 95% for MRSA and P. aeruginosa PAO1, respectively. Furthermore, the anticancer activity of Al2O3:Cr/Cdot NPs was assessed using C26 cells, demonstrating enhanced cytotoxicity upon UVA exposure. The NPs exhibited an inhibitory concentration (IC50) of 20 μg/mL without UVA exposure, decreasing to 10 μg/mL with UVA exposure, highlighting the synergistic effect of UVA light in enhancing cytotoxicity. Overall, these findings underscore the significant potential of Al2O3:Cr/Cdot NPs as multifunctional agents for addressing drug-resistant bacteria and advancing cancer therapy, offering promising avenues for nanomedicine research and development.
本研究旨在通过溶胶-凝胶法,利用芦荟提取的碳量子点(Cdot)和掺杂铬的氧化铝纳米粒子(Al2O3:Cr/Cdot NPs)合成一种新型抗菌抗癌纳米制剂。X 射线衍射(XRD)分析确认了尺寸范围为 10-12 纳米的结晶 NPs,而能量色散 X 射线光谱(EDS)则显示了它们的元素组成,不含杂质。傅立叶变换红外光谱(FT-IR)显示,Cdot 和 Al2O3:Cr NPs 之间存在很强的相互作用,形成了坚固的异质结构。扫描电子显微镜(SEM)和透射电子显微镜(TEM)图像提供了单分散球形 NPs 的直观确认,确保了进一步应用的一致性。对活性氧(ROS)的评估表明,Al2O3:Cr/Cdot NPs 能产生光动力疗法所必需的单线态氧和羟基自由基。最低抑菌浓度(MIC)测试表明,Al2O3:Cr/Cdot NPs 对耐药细菌具有强大的抗菌活性,对 MRSA 和铜绿假单胞菌 PAO1 的生物膜形成的抑制率分别为 89% 和 95%。此外,还使用 C26 细胞对 Al2O3:Cr/Cdot NPs 的抗癌活性进行了评估,结果表明其在 UVA 暴露下具有更强的细胞毒性。在没有 UVA 暴露的情况下,NPs 的抑制浓度(IC50)为 20 μg/mL,而在 UVA 暴露的情况下,抑制浓度降至 10 μg/mL,这凸显了 UVA 光在增强细胞毒性方面的协同效应。总之,这些发现强调了 Al2O3:Cr/Cdot NPs 作为多功能制剂在解决耐药细菌问题和促进癌症治疗方面的巨大潜力,为纳米医学的研究和开发提供了广阔的前景。
{"title":"Development of a novel nanoformulation based on aloe vera-derived carbon quantum dot and chromium-doped alumina nanoparticle (Al2O3:Cr@Cdot NPs): evaluating the anticancer and antimicrobial activities of nanoparticles in photodynamic therapy","authors":"Merat Karimi, Mina Homayoonfal, Mostafa Zahedifar, Amirreza Ostadian, Reyhaneh Adibi, Bahareh Mohammadzadeh, Arash Raisi, Fatemeh Ravaei, Somaye Rashki, Mahsa Khakbraghi, Michael Hamblin, Zahra Kheirkhah, Ehsan Sadeghi, Majid Nejati, Hamed Mirzaei","doi":"10.1186/s12645-024-00260-8","DOIUrl":"https://doi.org/10.1186/s12645-024-00260-8","url":null,"abstract":"The objective of this study was to synthesize a novel antibacterial and anticancer nanoformulation using aloe vera-derived carbon quantum dots (Cdot) and chromium-doped alumina nanoparticles (Al2O3:Cr/Cdot NPs) via a sol–gel method. X-ray diffraction (XRD) analysis confirmed crystalline NPs with a size range of 10–12 nm, while energy-dispersive X-ray spectroscopy (EDS) revealed their elemental composition without impurities. Fourier-transform infrared spectroscopy (FT-IR) indicated strong interactions between Cdot and Al2O3:Cr NPs, forming a robust heterostructure. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) images provided visual confirmation of monodisperse, spherical NPs, ensuring uniformity for further applications. Evaluation of reactive oxygen species (ROS) demonstrated superior generation of singlet oxygen and hydroxyl radicals by Al2O3:Cr/Cdot NPs, essential for photodynamic therapy. Minimum inhibitory concentration (MIC) tests revealed potent antibacterial activity against drug-resistant bacteria, inhibiting biofilm formation by 89% and 95% for MRSA and P. aeruginosa PAO1, respectively. Furthermore, the anticancer activity of Al2O3:Cr/Cdot NPs was assessed using C26 cells, demonstrating enhanced cytotoxicity upon UVA exposure. The NPs exhibited an inhibitory concentration (IC50) of 20 μg/mL without UVA exposure, decreasing to 10 μg/mL with UVA exposure, highlighting the synergistic effect of UVA light in enhancing cytotoxicity. Overall, these findings underscore the significant potential of Al2O3:Cr/Cdot NPs as multifunctional agents for addressing drug-resistant bacteria and advancing cancer therapy, offering promising avenues for nanomedicine research and development.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"27 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141253673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
As1411-modified liposomes to enhance drug utilization and augment the anti-tumor efficacy As1411 改性脂质体提高药物利用率并增强抗肿瘤疗效
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-05-14 DOI: 10.1186/s12645-024-00262-6
Danhuan Zhang, Lingyun Chen, Yang Zhao, Hao Ni, Qiuying Quan, Jun Ma, Lingchuan Guo
The utilization of liposomes in drug delivery has garnered significant attention due to their efficient drug loading capacity and excellent biocompatibility, rendering them a promising platform for tumor therapy. However, the average size of liposomes ~ 100 nm leads to liposomes being susceptible to hepatic and renal metabolism to excretion outside the body leading to poor drug delivery efficiency with a total utilization rate of less than 0.7%, resulting in unfavorable treatment outcomes. We have developed a novel liposome platform equipped with tumor surface nucleolin-targeting capacity to enhance drug accumulation at the tumor in vivo. The encapsulation of doxorubicin through thin film hydration has resulted in the formation of D@L-AS1411. Through in vivo experiments, we have demonstrated the effective accumulation of D@L-AS1411 at the tumor site and its ability to improve doxorubicin utilization rates by 40%. Additionally, D@L-AS1411 induces immunogenic death of tumor cells, release of tumor-associated antigens, upregulation of calreticulin expression, and recruitment of active T cell infiltration, and ultimately improves the therapeutic efficacy against tumors (70%). Based on the nucleic acid aptamer AS1411, D@L-1411 is developed to specifically enhance the accumulation of Dox at tumor sites, thereby inhibiting and enhancing the anti-tumor effect. In summary, this study not only provides an efficient tumor-targeting delivery platform but also contributes to the improvement of chemotherapy–immunotherapy combination for tumor treatment strategy in the clinic.
脂质体具有高效的载药能力和良好的生物相容性,是一种前景广阔的肿瘤治疗平台,因此,利用脂质体给药已引起广泛关注。然而,由于脂质体的平均尺寸约为 100 nm,因此脂质体容易被肝脏和肾脏代谢排出体外,导致药物输送效率低下,总利用率低于 0.7%,造成不利的治疗结果。我们开发了一种新型脂质体平台,该平台具有肿瘤表面核苷酸靶向能力,可增强药物在体内肿瘤处的蓄积。通过薄膜水合包封多柔比星,形成了 D@L-AS1411。通过体内实验,我们证明了 D@L-AS1411 在肿瘤部位的有效蓄积,并能将多柔比星的利用率提高 40%。此外,D@L-AS1411 还能诱导肿瘤细胞免疫性死亡、释放肿瘤相关抗原、上调钙调蛋白表达、招募活性 T 细胞浸润,最终提高对肿瘤的疗效(70%)。基于核酸适配体 AS1411 开发的 D@L-1411 可特异性增强 Dox 在肿瘤部位的蓄积,从而抑制和增强抗肿瘤效果。总之,这项研究不仅提供了一种高效的肿瘤靶向递送平台,而且有助于改进化疗-免疫疗法联合治疗肿瘤的临床策略。
{"title":"As1411-modified liposomes to enhance drug utilization and augment the anti-tumor efficacy","authors":"Danhuan Zhang, Lingyun Chen, Yang Zhao, Hao Ni, Qiuying Quan, Jun Ma, Lingchuan Guo","doi":"10.1186/s12645-024-00262-6","DOIUrl":"https://doi.org/10.1186/s12645-024-00262-6","url":null,"abstract":"The utilization of liposomes in drug delivery has garnered significant attention due to their efficient drug loading capacity and excellent biocompatibility, rendering them a promising platform for tumor therapy. However, the average size of liposomes ~ 100 nm leads to liposomes being susceptible to hepatic and renal metabolism to excretion outside the body leading to poor drug delivery efficiency with a total utilization rate of less than 0.7%, resulting in unfavorable treatment outcomes. We have developed a novel liposome platform equipped with tumor surface nucleolin-targeting capacity to enhance drug accumulation at the tumor in vivo. The encapsulation of doxorubicin through thin film hydration has resulted in the formation of D@L-AS1411. Through in vivo experiments, we have demonstrated the effective accumulation of D@L-AS1411 at the tumor site and its ability to improve doxorubicin utilization rates by 40%. Additionally, D@L-AS1411 induces immunogenic death of tumor cells, release of tumor-associated antigens, upregulation of calreticulin expression, and recruitment of active T cell infiltration, and ultimately improves the therapeutic efficacy against tumors (70%). Based on the nucleic acid aptamer AS1411, D@L-1411 is developed to specifically enhance the accumulation of Dox at tumor sites, thereby inhibiting and enhancing the anti-tumor effect. In summary, this study not only provides an efficient tumor-targeting delivery platform but also contributes to the improvement of chemotherapy–immunotherapy combination for tumor treatment strategy in the clinic.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"2016 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140940172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanoparticle delivery of si-Notch1 modulates metabolic reprogramming to affect 5-FU resistance and cell pyroptosis in colorectal cancer 纳米颗粒递送 si-Notch1 可调节代谢重编程,从而影响结直肠癌的 5-FU 抗药性和细胞热解作用
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-04-12 DOI: 10.1186/s12645-024-00259-1
Dan-dan Li, Jia-cheng Jin, Xuan-wen Liu, Shu-yang Liu, Fu-jian Ji, Tong Liu
Nanocarrier delivery of small interfering RNAs (siRNAs) to silence cancer-associated genes is a promising method for cancer treatment. Here, we explored the role and mechanisms of PLAG NPs-delivered si-Notch1 in colorectal cancer (CRC). High Notch1 expression was observed in both sensitive and resistant CRC tissues and cells. Notch1 silencing repressed proliferation and facilitates apoptosis of resistant CRC cells, and suppressed glycolysis and promoted pyroptosis in resistant CRC cells. Notch1 directly interacts with PCAF. Notch1 knockdown’s suppressive effect on glycolysis was reversed by overexpression of PCAF. Moreover, a nanocarrier called PLAG NPs was built with a higher delivery efficiency compared with lipo2000. Si-Notch1 delivered by PLAG NPs efficiently overcame the CRC cells’ 5-FU resistance and facilitated pyroptosis in a CRC mouse model. PLAG NPs carrying si-Notch1 had a great advantage in the extension of half-life circulation and targeting ability, providing a theoretical foundation for precise clinical treatment of CRC.
纳米载体递送小干扰 RNA(siRNA)以沉默癌症相关基因是一种很有前景的癌症治疗方法。在此,我们探讨了PLAG NPs递送的si-Notch1在结直肠癌(CRC)中的作用和机制。在敏感和耐药的 CRC 组织和细胞中都观察到了 Notch1 的高表达。沉默Notch1可抑制耐药CRC细胞的增殖并促进其凋亡,还可抑制耐药CRC细胞的糖酵解并促进其热凋亡。Notch1与PCAF直接相互作用。Notch1基因敲除对糖酵解的抑制作用被过表达PCAF所逆转。此外,与lipo2000相比,一种名为PLAG NPs的纳米载体具有更高的递送效率。通过PLAG NPs递送的Si-Notch1能有效克服CRC细胞对5-FU的耐药性,并在CRC小鼠模型中促进其热休克。携带si-Notch1的PLAG NPs在延长半衰期循环和靶向能力方面具有很大优势,为临床精准治疗CRC提供了理论基础。
{"title":"Nanoparticle delivery of si-Notch1 modulates metabolic reprogramming to affect 5-FU resistance and cell pyroptosis in colorectal cancer","authors":"Dan-dan Li, Jia-cheng Jin, Xuan-wen Liu, Shu-yang Liu, Fu-jian Ji, Tong Liu","doi":"10.1186/s12645-024-00259-1","DOIUrl":"https://doi.org/10.1186/s12645-024-00259-1","url":null,"abstract":"Nanocarrier delivery of small interfering RNAs (siRNAs) to silence cancer-associated genes is a promising method for cancer treatment. Here, we explored the role and mechanisms of PLAG NPs-delivered si-Notch1 in colorectal cancer (CRC). High Notch1 expression was observed in both sensitive and resistant CRC tissues and cells. Notch1 silencing repressed proliferation and facilitates apoptosis of resistant CRC cells, and suppressed glycolysis and promoted pyroptosis in resistant CRC cells. Notch1 directly interacts with PCAF. Notch1 knockdown’s suppressive effect on glycolysis was reversed by overexpression of PCAF. Moreover, a nanocarrier called PLAG NPs was built with a higher delivery efficiency compared with lipo2000. Si-Notch1 delivered by PLAG NPs efficiently overcame the CRC cells’ 5-FU resistance and facilitated pyroptosis in a CRC mouse model. PLAG NPs carrying si-Notch1 had a great advantage in the extension of half-life circulation and targeting ability, providing a theoretical foundation for precise clinical treatment of CRC.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"121 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140586129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing colorectal cancer therapy with biosynthesized cobalt oxide nanoparticles: a study on their antioxidant, antibacterial, and anticancer efficacy 利用生物合成的氧化钴纳米粒子推进结直肠癌治疗:关于其抗氧化、抗菌和抗癌功效的研究
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-04-05 DOI: 10.1186/s12645-024-00258-2
Fateme Momen Eslamiehei, Mansour Mashreghi, Maryam M. Matin
Colorectal cancer (CRC) ranks as the third most common cancer globally and the second leading cause of cancer-related mortality. Traditional chemotherapy, while effective, often results in significant side effects, highlighting the need for more efficient cancer therapies. Recent advancements in nanotechnology have led to the development of strategies that aim to minimize toxicity to normal cells by more precise targeting of cancer cells. In this context, cobalt oxide nanoparticles (Co3O4 NPs) have shown promising anticancer potential. Our study focuses on evaluating the antioxidant, antibacterial, and anticancer properties of Co3O4 NPs synthesized using Vibrio sp. VLC, a bioluminescent bacterium. XRD and FTIR analyses confirmed the successful synthesis of Co3O4 NPs, which displayed spherical morphology with an average diameter of 60 nm. The nanoparticles demonstrated significant antioxidant and antibacterial activities. The MTT assay indicated that the NPs caused dose- and time-dependent toxicity against CT26 cells, while exhibiting relatively lower toxicity towards normal cells. In vivo experiments further confirmed the significant tumor suppressive effects in BALB/c mice, with minimal side effects on the liver, spleen, and kidney tissues compared to the widespread toxicity of cisplatin. This study verifies the successful synthesis of Co3O4 NPs and their potent antioxidant, antibacterial, and anticancer activities. The biosynthesized Co3O4 NPs represent a promising targeted method for CRC therapy. However, further research is needed to elucidate their mechanism of action and also their application in the clinical phase.
结肠直肠癌(CRC)是全球第三大常见癌症,也是导致癌症相关死亡的第二大原因。传统的化疗虽然有效,但往往会产生严重的副作用,这凸显了人们对更高效癌症疗法的需求。纳米技术的最新进展促使人们开发出各种策略,旨在通过更精确地靶向癌细胞,最大限度地减少对正常细胞的毒性。在这方面,氧化钴纳米粒子(Co3O4 NPs)已显示出良好的抗癌潜力。我们的研究重点是评估利用弧菌 VLC(一种生物发光体)合成的 Co3O4 NPs 的抗氧化、抗菌和抗癌特性。VLC(一种生物发光细菌)合成的 Co3O4 NPs 的抗氧化、抗菌和抗癌特性。XRD 和 FTIR 分析证实成功合成了 Co3O4 NPs,其形态呈球形,平均直径为 60 nm。纳米粒子具有显著的抗氧化和抗菌活性。MTT 试验表明,纳米粒子对 CT26 细胞具有剂量和时间依赖性毒性,而对正常细胞的毒性相对较低。体内实验进一步证实,NPs 对 BALB/c 小鼠的肿瘤抑制效果显著,与顺铂的广泛毒性相比,对肝、脾和肾组织的副作用极小。这项研究验证了 Co3O4 NPs 的成功合成及其强大的抗氧化、抗菌和抗癌活性。生物合成的 Co3O4 NPs 是治疗 CRC 的一种很有前景的靶向方法。然而,要阐明其作用机制并将其应用于临床阶段,还需要进一步的研究。
{"title":"Advancing colorectal cancer therapy with biosynthesized cobalt oxide nanoparticles: a study on their antioxidant, antibacterial, and anticancer efficacy","authors":"Fateme Momen Eslamiehei, Mansour Mashreghi, Maryam M. Matin","doi":"10.1186/s12645-024-00258-2","DOIUrl":"https://doi.org/10.1186/s12645-024-00258-2","url":null,"abstract":"Colorectal cancer (CRC) ranks as the third most common cancer globally and the second leading cause of cancer-related mortality. Traditional chemotherapy, while effective, often results in significant side effects, highlighting the need for more efficient cancer therapies. Recent advancements in nanotechnology have led to the development of strategies that aim to minimize toxicity to normal cells by more precise targeting of cancer cells. In this context, cobalt oxide nanoparticles (Co3O4 NPs) have shown promising anticancer potential. Our study focuses on evaluating the antioxidant, antibacterial, and anticancer properties of Co3O4 NPs synthesized using Vibrio sp. VLC, a bioluminescent bacterium. XRD and FTIR analyses confirmed the successful synthesis of Co3O4 NPs, which displayed spherical morphology with an average diameter of 60 nm. The nanoparticles demonstrated significant antioxidant and antibacterial activities. The MTT assay indicated that the NPs caused dose- and time-dependent toxicity against CT26 cells, while exhibiting relatively lower toxicity towards normal cells. In vivo experiments further confirmed the significant tumor suppressive effects in BALB/c mice, with minimal side effects on the liver, spleen, and kidney tissues compared to the widespread toxicity of cisplatin. This study verifies the successful synthesis of Co3O4 NPs and their potent antioxidant, antibacterial, and anticancer activities. The biosynthesized Co3O4 NPs represent a promising targeted method for CRC therapy. However, further research is needed to elucidate their mechanism of action and also their application in the clinical phase. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"117 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140586209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypobaric hypoxia exposure regulates tissue distribution of nanomedicine for enhanced cancer therapy 低压缺氧暴露可调节纳米药物的组织分布,增强癌症治疗效果
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-04-02 DOI: 10.1186/s12645-024-00257-3
Ye Tao, Zhongping Chen
Effective drug delivery of nanomedicines to targeted sites remains challenging. Given that hypobaric hypoxia and hyperbaric oxygen exposure can significantly change pharmacokinetics of drugs, it is interesting to determine whether they can regulate tissue distribution of nanomedicine, especially in tumor, for enhanced cancer therapy. Hypobaric hypoxia exposure improved the pharmacokinetics of paclitaxel-loaded liposomes and facilitated their distribution in the heart and liver, whereas hyperbaric oxygen exposure did not benefit and even impaired the pharmacokinetics and distribution. Particularly, both hypobaric hypoxia and hyperbaric oxygen exposure could not improve the distribution in subcutaneous tumor. Thus, we constructed orthotopic liver tumor model and discussed whether high distribution of the liposomal nanomedicine in the liver, facilitated by hypobaric hypoxia exposure, could ensure their effective accumulation in liver tumor for enhanced cancer therapy. The liposomal nanomedicine with adjuvant hypobaric hypoxia exposure significantly inhibited the growth of orthotopic liver tumor for prolonged survival time, achieved by hypobaric hypoxia-promoted accumulation at tumor sites of the liver. It might be the first example of the application of adjuvant intermittent hypobaric hypoxia exposure in treating liver cancer.
将纳米药物有效地输送到目标部位仍然具有挑战性。鉴于低压缺氧和高压氧暴露能显著改变药物的药代动力学,因此确定它们是否能调节纳米药物的组织分布,尤其是在肿瘤中的分布,以增强癌症治疗效果是很有意义的。低压氧暴露改善了紫杉醇脂质体的药代动力学,并促进了其在心脏和肝脏中的分布,而高压氧暴露则对其药代动力学和分布无益,甚至有损。特别是,低压缺氧和高压氧暴露都不能改善其在皮下肿瘤中的分布。因此,我们构建了正位肝脏肿瘤模型,并探讨了低压缺氧暴露是否能促进纳米脂质体药物在肝脏的高分布,从而确保其在肝脏肿瘤中的有效蓄积,以增强肿瘤治疗效果。辅助低压氧暴露的纳米脂质体药物能显著抑制肝脏肿瘤的生长,延长存活时间,这是通过低压氧促进在肝脏肿瘤部位的积累实现的。这可能是应用间歇性低压氧暴露辅助治疗肝癌的首个实例。
{"title":"Hypobaric hypoxia exposure regulates tissue distribution of nanomedicine for enhanced cancer therapy","authors":"Ye Tao, Zhongping Chen","doi":"10.1186/s12645-024-00257-3","DOIUrl":"https://doi.org/10.1186/s12645-024-00257-3","url":null,"abstract":"Effective drug delivery of nanomedicines to targeted sites remains challenging. Given that hypobaric hypoxia and hyperbaric oxygen exposure can significantly change pharmacokinetics of drugs, it is interesting to determine whether they can regulate tissue distribution of nanomedicine, especially in tumor, for enhanced cancer therapy. Hypobaric hypoxia exposure improved the pharmacokinetics of paclitaxel-loaded liposomes and facilitated their distribution in the heart and liver, whereas hyperbaric oxygen exposure did not benefit and even impaired the pharmacokinetics and distribution. Particularly, both hypobaric hypoxia and hyperbaric oxygen exposure could not improve the distribution in subcutaneous tumor. Thus, we constructed orthotopic liver tumor model and discussed whether high distribution of the liposomal nanomedicine in the liver, facilitated by hypobaric hypoxia exposure, could ensure their effective accumulation in liver tumor for enhanced cancer therapy. The liposomal nanomedicine with adjuvant hypobaric hypoxia exposure significantly inhibited the growth of orthotopic liver tumor for prolonged survival time, achieved by hypobaric hypoxia-promoted accumulation at tumor sites of the liver. It might be the first example of the application of adjuvant intermittent hypobaric hypoxia exposure in treating liver cancer.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"17 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140586144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer 用于治疗三阴性乳腺癌的 PARP 抑制剂 Talazoparib 和 CDK 抑制剂 dinaciclib 的纳米鸡尾酒
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-03-23 DOI: 10.1186/s12645-023-00240-4
Paige Baldwin, Shicheng Yang, Adrienne Orriols, Sherrie Wang, Needa Brown, Srinivas Sridhar
The addition of the cyclin dependent kinase inhibitor (CDKi) dinaciclib to Poly-(ADP-ribose) polymerase inhibitor (PARPi) therapy is a strategy to overcome resistance to PARPi in tumors that exhibit homologous recombination (HR) deficiencies as well as to expand PARPi therapy to tumors that do not exhibit HR deficiencies. However, combination therapy using pathway inhibitors has been plagued by an inability to administer doses sufficient to achieve clinical benefit due to synergistic toxicities. Here we sought to combine nanoformulations of the PARPi talazoparib, nTLZ, and the CDKi dinaciclib, nDCB, in a nano-cocktail to enhance therapeutic efficacy while maintaining lower doses. Pharmacokinetics of nDCB were assessed to ensure it is compatible with nTLZ. nDCB was combined with nTLZ to generate a nano-cocktail nDCB:nTLZ, which elicits greater cell death in vitro compared to the combination of the free drugs. MDA-MB-231-LUC-D3H2LN xenografts were utilized to assess therapeutic efficacy of the nano-cocktail in terms of tumor progression. Administration of the nano-cocktail significantly slowed tumor progression in the HR proficient animal model compared to administration of free talazoparib and free dinaciclib at the same doses. Histology of the liver, spleen, and kidneys revealed long-term treatment did not induce nanoparticle associated morphological changes. Complete blood count did not reveal any significant hematologic changes after treatment with either the free combination or nano-cocktail. The efficacy and toxicity data suggest that further dose escalation can be pursued in order to achieve a stronger response. These data suggest the administration of combination therapy through the nano-cocktail leads to a better response than the use of free compounds and is a promising strategy for implementing combination therapy in the clinic.
在聚-(ADP-核糖)聚合酶抑制剂(PARPi)疗法中加入细胞周期蛋白依赖性激酶抑制剂(CDKi)dinaciclib是一种策略,可以克服表现出同源重组(HR)缺陷的肿瘤对PARPi的耐药性,并将PARPi疗法扩展到没有表现出HR缺陷的肿瘤。然而,由于协同毒性,使用通路抑制剂的联合疗法一直受到无法施用足够剂量以获得临床疗效的困扰。在这里,我们试图将 PARPi 药物 talazoparib(nTLZ)和 CDKi 药物 dinaciclib(nDCB)的纳米制剂结合成纳米鸡尾酒,以提高疗效,同时保持较低的剂量。对 nDCB 的药代动力学进行了评估,以确保它与 nTLZ 的相容性。将 nDCB 与 nTLZ 结合生成了 nDCB:nTLZ 纳米鸡尾酒,在体外诱导细胞死亡的效果优于自由药物组合。利用MDA-MB-231-LUC-D3H2LN异种移植来评估纳米鸡尾酒在肿瘤进展方面的疗效。与相同剂量的游离talazoparib和游离dinaciclib相比,在HR熟练动物模型中施用纳米鸡尾酒能显著减缓肿瘤进展。肝脏、脾脏和肾脏的组织学检查显示,长期治疗并未诱发与纳米颗粒相关的形态学变化。全血细胞计数显示,游离复方或纳米鸡尾酒疗法均未引起任何明显的血液学变化。疗效和毒性数据表明,可以进一步加大剂量,以获得更强的反应。这些数据表明,与使用游离化合物相比,通过纳米鸡尾酒进行联合治疗可获得更好的反应,是在临床上实施联合治疗的一种有前途的策略。
{"title":"A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer","authors":"Paige Baldwin, Shicheng Yang, Adrienne Orriols, Sherrie Wang, Needa Brown, Srinivas Sridhar","doi":"10.1186/s12645-023-00240-4","DOIUrl":"https://doi.org/10.1186/s12645-023-00240-4","url":null,"abstract":"The addition of the cyclin dependent kinase inhibitor (CDKi) dinaciclib to Poly-(ADP-ribose) polymerase inhibitor (PARPi) therapy is a strategy to overcome resistance to PARPi in tumors that exhibit homologous recombination (HR) deficiencies as well as to expand PARPi therapy to tumors that do not exhibit HR deficiencies. However, combination therapy using pathway inhibitors has been plagued by an inability to administer doses sufficient to achieve clinical benefit due to synergistic toxicities. Here we sought to combine nanoformulations of the PARPi talazoparib, nTLZ, and the CDKi dinaciclib, nDCB, in a nano-cocktail to enhance therapeutic efficacy while maintaining lower doses. Pharmacokinetics of nDCB were assessed to ensure it is compatible with nTLZ. nDCB was combined with nTLZ to generate a nano-cocktail nDCB:nTLZ, which elicits greater cell death in vitro compared to the combination of the free drugs. MDA-MB-231-LUC-D3H2LN xenografts were utilized to assess therapeutic efficacy of the nano-cocktail in terms of tumor progression. Administration of the nano-cocktail significantly slowed tumor progression in the HR proficient animal model compared to administration of free talazoparib and free dinaciclib at the same doses. Histology of the liver, spleen, and kidneys revealed long-term treatment did not induce nanoparticle associated morphological changes. Complete blood count did not reveal any significant hematologic changes after treatment with either the free combination or nano-cocktail. The efficacy and toxicity data suggest that further dose escalation can be pursued in order to achieve a stronger response. These data suggest the administration of combination therapy through the nano-cocktail leads to a better response than the use of free compounds and is a promising strategy for implementing combination therapy in the clinic.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"102 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140199659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Nanotechnology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1